Added successfully to RFQ list

Added successfully to compare list

Our clients

o2h discovery provides a wide range of biochemical assay services to support various stages of drug discovery and preclinical research. Our team of bio scientists possess expertise in crafting and sustaining customized, reliable assays that encompass a wide array of targets. Whether kits sourced from reputable commercial vendors or meticulously designed in-house to align with our clients’ expectations, we can support in the development of screening assays for a plethora of enzyme classes e.g. Kinases, Peptidases, Phosphatases. We can aid in the understanding of enzyme kinetics, substrate post translational modification, ATP consumption/ADP formation as a result of kinase reaction, product formation etc. Aspects like Km, Vmax and the nature of  small molecule inhibition can be addressed for your compounds.

Biochemical assays often rely on various detection methods to measure and analyse the activity of specific biomolecules. These technologies are chosen based on the specific characteristics of the biomolecules being analysed, required sensitivity, specificity and the assay objective. Each technology has its advantages and limitations making it important to select the most appropriate one for a given experiment.

Here are some of the detection technologies implemented in our biochemical assays –

  • Fluorescence Spectroscopy detects and quantifies fluorescent molecules which can be used as labels or probes offering high sensitivity and specificity
  • Luminescence Detection involves measurement of emitted light such as bioluminescence (e.g., luciferase assays) or chemiluminescence (e.g., enzyme-linked chemiluminescent assays, ECL)
  • Colorimetry relies on the change in colour of a reaction product or a biomolecule in response to a specific analyte often used in enzyme activity assays
  • Fluorescence Resonance Energy Transfer (FRET) measures the transfer of energy between two fluorophores (donor and acceptor) when in close proximity allowing for the study of molecular interactions and conformational changes
  • Homogeneous Time-Resolved Fluorescence (HTRF) is a no-wash technology and combines FRET technology with time-resolved measurement of fluorescence, eliminating short-lived background fluorescence. Ideal platform used for drug target studies for medium to high-throughput screening
  • Bioluminescence Resonance Energy Transfer (BRET) similar to FRET but uses bioluminescent molecules, such as luciferase to study molecular interactions. Extensively used to address in- cell target engagement e.g. NanoBRET, Targeted Protein Degradation (TPD)
  • AlphaScreen® (Amplified Luminescent Proximity Homogeneous Assay) particularly valuable in medium to high-throughput screening assays used for the detection and quantification of biomolecular interactions, formation/depletion of a substrate or product, post-translational modifications and biochemical processes.

To know more about our biology services offering or to request our brochure, please reach out to us at discovery@o2h.com.

our team

Sunil

Sunil Shah

CEO - o2h Ventures and Co-Founder - o2h discovery

Sunil's Biography

Read more

Sunil Shah

CEO - o2h Ventures and Co-Founder - o2h discovery

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University


Connect on linkedin

prashant shah

Prashant Shah

CEO - o2h discovery and Co-Founder - o2h group

Prashant's Biography

Read more

Prashant Shah

CEO - o2h discovery and Co-Founder - o2h group

Prashant is a serial entrepreneur in life sciences and tech in which one of those companies was acquired by a public company. He is currently active in seed investing (a portfolio of ~50 companies), product/IP development, services, and building lab/office infrastructure. The early career was with the Strategy group at Accenture. He has a BEng, an MSc, in which he worked on the Human Genome Program at the Sanger Centre, and an MPhil in Management from the Judge Institute. Prashant is also a General Partner in the o2h SEIS/EIS Human Health Funds.


Connect on linkedin

Andy Morley

Andy Morley

Chief Scientific Officer

Andy's Biography

Read more

Andy Morley

Chief Scientific Officer

Andy is a highly experienced and accomplished Medicinal Chemist with over 25 years of experience in major pharmaceutical companies such as Sanofi-Aventis and AstraZeneca. He has extensive experience across all phases of drug discovery and has played a key role in the development of five candidates that have reached clinical trials. Andy is a prolific author and inventor, with over 55 publications and patents to his name. Since 2013, he has been working full-time with o2h Limited, where he leads the scientific evaluation of investment opportunities and provides scientific support. He has also served as CSO for two early-stage collaborations within the o2h Ventures portfolio, demonstrating his ability to successfully guide drug discovery projects from concept to clinical development.


Connect on linkedin

Nilesh Dagia

Nilesh Dagia

Chief Special Projects Officer

Nilesh's Biography

Read more

Nilesh Dagia

Chief Special Projects Officer

Nilesh leads the global operations of o2h group covering a wide range of innovation led investment, life-science and technology businesses. He is also overseeing the development and execution of the new o2h discovery Shirish Research Centre in Ahmedabad, India. Prior to joining o2h group, Nilesh worked with Piramal Group in various capacities including as an Alliance Manager for a risk-share oncology-based collaboration with a US Big Pharma and has also worked as the Head of Biology in Piramal Discovery solutions. Nilesh obtained his Ph.D. from Ohio University and completed a post-doc in Immunology, Stem Cells and Regenerative Medicine at Harvard Medical School. He is the author and inventor of >30 life science patents and publications. He received the Young Scientist of India award from OPPI in 2010.


Connect on linkedin

o2h group launched revolutionary project management app for drug discovery

o2h group launched revolutionary project management app for drug discovery. The app’s full suite of project management tools is available exclusively to live project collaborators and a lighter version is open for researchers looking for a quote for the synthesis of small molecules.

the influencer biotech bootcamp

Hauxton House, Mill Scitech Park, Cambridge

The world’s first biotech bootcamp, including the quintet influencer community that is the creative force driving biotech.

View more

latest news

Read about some of the most recent developments including research collaborations at o2h discovery

speak to a member of our team

Contact Us